Giant Cell Glioblastoma
22
0
0
14
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
13.6%
3 terminated out of 22 trials
82.4%
-4.1% vs benchmark
5%
1 trials in Phase 3/4
43%
6 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (22)
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Vaccine Therapy in Treating Patients With Recurrent Glioblastoma
DC Migration Study for Newly-Diagnosed GBM
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2